AlphAIAlphAI — Financial news for AI agents
foodsafetynews.com$PRGO

Congresswoman has concerns about sale of infant formula company

MeridianMade, led by ByHeart co-founders Ron Belldegrun and Mia Funt, plans to acquire Dublin-based Perrigo for $175 million, with the sale expected to close in early 2027.

Original reporting
foodsafetynews.com
Published Nov 4, 2026, 5:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 5:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Congresswoman has concerns about sale of infant formula company — source image
Source · foodsafetynews.com
Decision brief

The 30-second read

$PRGOBullishMed
01

Why it matters

The acquisition could reshape market share dynamics and affect pricing power in the sector.

02

Market read

First‑report M&A news likely to move PRGO stock; sector consolidation implications.

03

What to watch

Regulatory scrutiny of infant formula market and possible antitrust review.

Relevance 8/10Novelty 8/10Timing: announcement today

Background

MeridianMade, founded by former ByHeart executives, is entering the infant formula market by acquiring Perrigo.

Company-level read

Ticker impact

$PRGOBullishHigh confidence
Context

MeridianMade announced a $175 million cash acquisition of Perrigo, a first‑report M&A deal.

Expected impact

likely upward pressure as the market prices in the acquisition premium

Evidence & confidence

First disclosure of a cash buyout at a material price level for a mid‑cap listed company.

Market effects

Sector

Potential consolidation in the infant formula and nutrition sector.

Regional

U.S. consumer‑goods market may see modest reallocation of capital.

Global

Limited to nutrition segment; no broad market impact.

Counterpoint

What could challenge this read

Deal size is modest; integration risks could weigh on long‑term performance.

Key entities

  • Company
    MeridianMade

    Newly formed infant formula company led by Ron Belldegrun and Mia Funt.

  • Company
    Perrigo

    Dublin‑based infant formula producer being acquired for $175 million.

Read at source← All news

StoryPerrigo to sell infant formula business to MeridianMade for up to $175 million

Also covered by

1 outlet

Related articles

$PRGOMed

Perrigo Q3 Earnings Call Highlights

Perrigo (PRGO) reported Q3 earnings with net sales declines in self-care and specialty care segments. Adjusted EPS fell to 61 cents, with a lower tax rate providing some benefit. The company expects 2026 sales declines and adjusted EPS of $2.15-$2.35. Perrigo is divesting infant formula and other businesses to simplify operations and reduce debt. Cash and debt at quarter-end were $437M and $3.3B, respectively.

finance.yahoo.com
$PRGOHigh

Perrigo Sets 2026 All-In Adjusted EPS Outlook at $2.25 to $2.45

Perrigo Company plc set its 2026 adjusted diluted EPS outlook at $2.25 to $2.45, excluding its infant formula unit, which it classified as discontinued operations. Core EPS is expected at $2.15 to $2.35, with core sales declining 2.5% to 3.6% and an adjusted operating margin of 14% to 15%. The company plans to sell the unit to MeridianMade for up to $175 million, with $40 million upfront.

tokenpost.com
$PRGOMed

Perrigo Co PLC (PRGO) (Q3 2026) Earnings Call Highlights: Margin Gains and Share Growth

Perrigo (PRGO) reported Q3 2026 core net sales declined 1.7% YoY, with organic sales down 1.1%. Adjusted gross margin fell 140 bps to 37.9%. The company updated its 2026 outlook downward, citing retailer inventory positioning and European softness. Interim CEO Albert Manzone highlighted share gains, innovation, and e-commerce growth as priorities. The infant formula divestiture is complete, and oral care is under strategic review.

finance.yahoo.com
$PRGOMed

Perrigo (PRGO) Q3 2026 Earnings Call Transcript

Perrigo (PRGO) reported Q3 2026 earnings, highlighting operational improvements and a strategic focus on simplifying the business. The company saw sequential improvements in core net sales and operating margins, with a 1.7% decline in sales and a 14.3% operating margin. Perrigo announced the sale of its infant formula business and updated its 2026 outlook, reflecting divestments and market conditions.

finance.yahoo.com
$PRGOMed

Perrigo Company plc Q3 2026 Earnings Call Summary

Perrigo reported Q3 2026 improvements in core adjusted operating margins (12.8% to 14.3%) due to its Three-S plan. The company is simplifying its portfolio, including divesting the infant formula business, to focus on higher-margin categories. Market share gains in U.S. and European OTC brands were noted, along with e-commerce expansion. Management updated 2026 and 2027 outlooks, emphasizing debt reduction and operational improvements. Q3 results included a $4.5M one-time tariff benefit.

finance.yahoo.com